General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder

INTRODUCTION: Mood stabilizers are the recommended treatment for patients who receive a diagnosis of bipolar disorder. Because of the necessity of mood stabilizer treatment in patients with bipolar disorder and the extent of pharmacokinetic and pharmacodynamic principles involved, the purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ware, Kenric, Tillery, Erika, Linder, Lauren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009247/
https://www.ncbi.nlm.nih.gov/pubmed/29955448
http://dx.doi.org/10.9740/mhc.2016.01.054
_version_ 1783333338866515968
author Ware, Kenric
Tillery, Erika
Linder, Lauren
author_facet Ware, Kenric
Tillery, Erika
Linder, Lauren
author_sort Ware, Kenric
collection PubMed
description INTRODUCTION: Mood stabilizers are the recommended treatment for patients who receive a diagnosis of bipolar disorder. Because of the necessity of mood stabilizer treatment in patients with bipolar disorder and the extent of pharmacokinetic and pharmacodynamic principles involved, the purpose of this review is to summarize the pharmacokinetic principles of lithium in addition to the pharmacodynamics of lithium, carbamazepine, lamotrigine, and valproic acid/valproate. METHODS: Practice guidelines, review articles, and clinical trials were located using online databases PubMed, CINAHL, IDIS, and Medline. Search terms included at least one of the following: bipolar disorder, carbamazepine, lamotrigine, lithium, mood stabilizers, pharmacokinetics, pharmacodynamics, valproate, and valproic acid. Online clinical databases Dynamed® and Lexicomp® were also used in the study. RESULTS: Mood stabilizers collectively possess distinct qualities that are closely regarded before, during, and after therapeutic initiation. Individual patient characteristics, coupled with these observed traits, add to the complexity of selecting the most optimal neurologic agent. Each medication discussed uniquely contributes to both the maintenance and restoration of overall patient well-being. DISCUSSION: Introduction of mood stabilizers into drug regimens is often done in the presence of an array of mitigating factors. Safety and efficacy measures are commonly used to gauge desired results. Careful monitoring of patients' responses to selected therapies is paramount for arriving at appropriate clinical outcomes.
format Online
Article
Text
id pubmed-6009247
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-60092472018-06-28 General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder Ware, Kenric Tillery, Erika Linder, Lauren Ment Health Clin Literature Reviews INTRODUCTION: Mood stabilizers are the recommended treatment for patients who receive a diagnosis of bipolar disorder. Because of the necessity of mood stabilizer treatment in patients with bipolar disorder and the extent of pharmacokinetic and pharmacodynamic principles involved, the purpose of this review is to summarize the pharmacokinetic principles of lithium in addition to the pharmacodynamics of lithium, carbamazepine, lamotrigine, and valproic acid/valproate. METHODS: Practice guidelines, review articles, and clinical trials were located using online databases PubMed, CINAHL, IDIS, and Medline. Search terms included at least one of the following: bipolar disorder, carbamazepine, lamotrigine, lithium, mood stabilizers, pharmacokinetics, pharmacodynamics, valproate, and valproic acid. Online clinical databases Dynamed® and Lexicomp® were also used in the study. RESULTS: Mood stabilizers collectively possess distinct qualities that are closely regarded before, during, and after therapeutic initiation. Individual patient characteristics, coupled with these observed traits, add to the complexity of selecting the most optimal neurologic agent. Each medication discussed uniquely contributes to both the maintenance and restoration of overall patient well-being. DISCUSSION: Introduction of mood stabilizers into drug regimens is often done in the presence of an array of mitigating factors. Safety and efficacy measures are commonly used to gauge desired results. Careful monitoring of patients' responses to selected therapies is paramount for arriving at appropriate clinical outcomes. College of Psychiatric & Neurologic Pharmacists 2016-03-08 /pmc/articles/PMC6009247/ /pubmed/29955448 http://dx.doi.org/10.9740/mhc.2016.01.054 Text en © 2016 CPNP. http://creativecommons.org/licenses/by-nc/3.0/ The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Literature Reviews
Ware, Kenric
Tillery, Erika
Linder, Lauren
General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title_full General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title_fullStr General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title_full_unstemmed General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title_short General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
title_sort general pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder
topic Literature Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009247/
https://www.ncbi.nlm.nih.gov/pubmed/29955448
http://dx.doi.org/10.9740/mhc.2016.01.054
work_keys_str_mv AT warekenric generalpharmacokineticpharmacodynamicconceptsofmoodstabilizersinthetreatmentofbipolardisorder
AT tilleryerika generalpharmacokineticpharmacodynamicconceptsofmoodstabilizersinthetreatmentofbipolardisorder
AT linderlauren generalpharmacokineticpharmacodynamicconceptsofmoodstabilizersinthetreatmentofbipolardisorder